CYTOSORBENTS CORPORATION
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.6M | $8.9M | $9.2M | $9.5M | $9.6M | $8.7M | $9.2M | $8.6M |
| Cost of Revenue | $2.6M | $2.7M | $2.4M | $2.8M | $2.8M | $2.5M | $2.9M | $3.4M |
| Gross Profit | $7.0M | $6.1M | $6.8M | $6.7M | $6.8M | $6.2M | $6.3M | $5.3M |
| Gross Margin | 73.2% | 69.2% | 73.7% | 70.3% | 70.9% | 71.1% | 68.4% | 61.0% |
| Operating Expenses | ||||||||
| Research & Development | $1.5M | $1.0M | — | — | $1.3M | $1.7M | — | $1.9M |
| SG&A Expense | $8.0M | $8.1M | $9.4M | $8.6M | $9.2M | $8.4M | $7.6M | $8.3M |
| Operating Income | $-2.6M | $-3.0M | $-4.4M | $-2.9M | $-3.6M | $-3.9M | $-3.4M | $-4.8M |
| Operating Margin | -27.4% | -34.3% | -47.5% | -30.2% | -37.6% | -44.6% | -37.1% | -56.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | $-3.6M | — | $-1.5M | $-9.4M | $-2.8M |
| Income Tax Expense | $0 | $0 | $0 | $-401.0K | $0 | $0 | — | $0 |
| Net Income | $-4.4M | $-5.1M | $-5.5M | $-3.2M | $1.9M | $-1.5M | $-7.6M | $-2.8M |
| Net Margin | -45.9% | -57.9% | -59.5% | -33.4% | 20.2% | -16.9% | -82.7% | -32.1% |
| EPS (Basic) | $-0.07 | $-0.08 | $-0.09 | $-0.05 | $0.03 | $-0.02 | $-0.14 | $-0.05 |
| EPS (Diluted) | $-0.07 | $-0.08 | $-0.09 | $-0.05 | $0.03 | $-0.02 | $-0.14 | $-0.05 |
| Shares Outstanding (Basic) | 62.8M | 62.7M | 62.2M | 62.8M | 62.6M | 60.7M | 54.4M | 54.5M |
| Shares Outstanding (Diluted) | 62.8M | 62.7M | 62.2M | 62.8M | 67.2M | 60.7M | 54.4M | 54.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |